Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study)
- 31 August 1995
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 26 (2) , 365-373
- https://doi.org/10.1016/0735-1097(95)80008-5
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.Circulation, 1994
- Time course of left ventricular function and coronary patency after saruplase vs streptokinase in acute myocardial infarctionEuropean Heart Journal, 1993
- Role of Heparin in Coronary ThrombolysisChest, 1992
- Thrombolysis, anticoagulation, and reocclusionThe American Journal of Cardiology, 1991
- Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarctionThe American Journal of Cardiology, 1991
- Conjunctive Antithrombotic and Thrombolytic Therapy for Coronary-Artery OcclusionNew England Journal of Medicine, 1990
- Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarctionThe American Journal of Cardiology, 1988
- Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.Circulation, 1986
- Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: Effect on regional blood flow, infarct size and hemostasisJournal of the American College of Cardiology, 1986
- Single-chain urokinase-type plasminogen activators: New hopes for clot-specific lysisEuropean Heart Journal, 1985